This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Investment

BioInvent discusses recent Pfizer immunotherapy alliance

Posted by on 14 July 2017
Share this article

Three years after setting out to turn BioInvent around, company president and CEO Michael Oredsson tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, how the company is developing its immunotherapy offering. With tumor-associated myeloid cells, BioInvent secured a deal with Pfizer at the end of 2016, while it intends to go it alone with its regulatory T cell approach.


Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Michael Oredsson – President and CEO, BioInvent

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down